Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $500.00 at Royal Bank Of Canada

Key Points

• Royal Bank of Canada has raised its price target for Alnylam Pharmaceuticals from $435.00 to $500.00, indicating a potential upside of 10.58% from the current stock price, while maintaining an "outperform" rating.
• Alnylam Pharmaceuticals recently reported positive earnings, earning $0.32 per share, surpassing estimates and showing a 17.3% increase in revenue year-over-year.
• Despite the positive outlook, some analysts, including Wall Street Zen, have downgraded the rating on Alnylam Pharmaceuticals from "strong-buy" to "buy," highlighting mixed sentiments among analysts regarding the stock.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Free Report) had its price target boosted by Royal Bank Of Canada from $435.00 to $500.00 in a report issued on Friday morning,Benzinga reports. Royal Bank Of Canada currently has an outperform rating on the biopharmaceutical company's stock.

A number of other equities research analysts also recently commented on ALNY. JPMorgan Chase & Co. upped their price objective on Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the company an "overweight" rating in a report on Wednesday, August 6th. Needham & Company LLC boosted their price target on Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the company a "buy" rating in a report on Thursday, July 31st. UBS Group increased their target price on shares of Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the stock a "buy" rating in a report on Friday, August 1st. HC Wainwright reissued a "buy" rating and issued a $570.00 price objective on shares of Alnylam Pharmaceuticals in a report on Tuesday, September 2nd. Finally, Morgan Stanley increased their price objective on shares of Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the company an "equal weight" rating in a research report on Friday, August 1st. Twenty-four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $439.58.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock traded down $3.09 during mid-day trading on Friday, reaching $455.84. The company's stock had a trading volume of 301,882 shares, compared to its average volume of 976,624. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. The company has a market cap of $59.75 billion, a P/E ratio of -184.55 and a beta of 0.32. Alnylam Pharmaceuticals has a 1-year low of $205.87 and a 1-year high of $484.21. The firm's 50-day moving average is $417.91 and its two-hundred day moving average is $326.74.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating analysts' consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The firm had revenue of $773.69 million for the quarter, compared to analyst estimates of $633.54 million. During the same period in the previous year, the business earned ($0.13) earnings per share. The company's revenue for the quarter was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, research analysts predict that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Colleen F. Reitan sold 18,000 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $467.60, for a total transaction of $8,416,800.00. Following the completion of the sale, the director directly owned 775 shares of the company's stock, valued at approximately $362,390. The trade was a 95.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Dennis A. Ausiello sold 31,448 shares of the company's stock in a transaction that occurred on Thursday, August 14th. The stock was sold at an average price of $436.58, for a total value of $13,729,567.84. Following the completion of the sale, the director directly owned 911 shares of the company's stock, valued at approximately $397,724.38. This represents a 97.18% decrease in their position. The disclosure for this sale can be found here. Insiders sold 75,594 shares of company stock valued at $33,968,256 in the last 90 days. Corporate insiders own 1.20% of the company's stock.

Institutional Trading of Alnylam Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. SVB Wealth LLC bought a new position in Alnylam Pharmaceuticals in the first quarter worth about $27,000. Park Square Financial Group LLC purchased a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at about $28,000. Whipplewood Advisors LLC raised its holdings in Alnylam Pharmaceuticals by 208.8% in the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 71 shares during the last quarter. Bessemer Group Inc. boosted its position in shares of Alnylam Pharmaceuticals by 176.9% during the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 69 shares during the last quarter. Finally, Atlantic Union Bankshares Corp purchased a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at approximately $30,000. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.